The next financial crisis will be sparked by the rise of giant daily dealing bond funds and ETFs, GLG’s top performing fixed income manager Jon Mawby has warned.
Matt Kamm, managing director of Artisan Partners, explains why, following their upswing, biotech stocks are still early in a pharmaceutical renaissance which should capture investor attention.
With monetary policy weakening the yen and a consumption tax rise at home, Japan's multinationals are the key to solving the country's problems - and the best bet for investors, says Neptune's Chris Taylor.
The Big Debate
The Big Debate is an online audio and video conferencing club with an audience comprising the UK's leading discretionary asset managers, top IFAs, and other investment professionals.
IW Fund Centre
Register here to get full access to all Investment Week's news and comment articles from our archive.
Updating your subscription status